Investors & partners
Innocell starts with a patient's own tumor cells. PhotonPharma is advancing the platform through clinical evaluation in recurrent epithelial ovarian cancer.
Contact the teamThe development rationale, and what remains to be demonstrated.
Innocell uses tumor-derived cells to retain a broad antigen repertoire. Riboflavin and ultraviolet light inactivate replication; the cells are administered with CpG1018.
The intended immune response is a mechanism under evaluation, not a claim of demonstrated clinical benefit.
How Innocell worksThe Phase 1 study at City of Hope evaluates safety and immunogenicity in recurrent epithelial ovarian cancer.
Registry record NCT06366490 was last updated March 27, 2026. Refer to the study record for current details; estimated dates are not completed milestones.
View the clinical studyThe development record
Explore the study, research and development milestones behind Innocell.
A study evaluating safety and immunogenicity in recurrent epithelial ovarian cancer.
Read the study recordPublished work includes a canine cancer case study and research in Vox Sanguinis. These are distinct from human clinical results.
Explore publicationsCancer vaccine compositions and methods of use. Issued April 22, 2025.
View the patentAn August 2021 announcement described an MOU to collaborate on Innocell development.
Read the announcementDevelopment priorities
The lead clinical program is distinct from the planned combination cohort and potential expansion into other solid tumors. Safety, immune response and clinical benefit must be assessed in the appropriate studies.
View the development pipelineMeet the people responsible for advancing the work.
Management and boardFor investment, partnering or scientific inquiries, tell us about your organization and your interest in the program.
Contact the teamInnocell is investigational and is not approved for commercial use.